ProQR director reports stock option holdings

ProQR Therapeutics N.V. director Bart Filius filed an initial ownership report detailing his stock option holdings.

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Bart Filius filed an initial ownership report detailing his stock option holdings. The Form 3 lists multiple options to purchase ordinary shares at fixed exercise prices, with expiration dates ranging from 2029 through 2035.

One option grant is noted as fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to his continued service. The filing reports holdings only and does not show any recent share purchases or sales.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Filius Bart

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 177,957 contracts (Direct)

Footnotes (5)

1. F1. Fully vested.
2. F2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
3. F3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
4. F4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
5. F5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ProQR (PRQR) Form 3 filing by Bart Filius show?

The Form 3 shows that director Bart Filius holds several stock options to buy ProQR ordinary shares at fixed exercise prices, expiring between 2029 and 2035. It is an initial ownership report and does not disclose any recent stock purchases or sales.

Are there any ProQR (PRQR) share purchases or sales in this Form 3?

No, this Form 3 does not report any share purchases or sales. It only lists existing stock option holdings for director Bart Filius, including their exercise prices, expiration dates and vesting schedules, as part of his initial statement of beneficial ownership.

What stock option vesting terms are disclosed for ProQR director Bart Filius?

The filing notes one grant is fully vested. Other grants vest 25% on January 1 of 2024, 2025, 2026 or 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, contingent on his continued service with ProQR.

What types of securities are reported in the ProQR (PRQR) Form 3?

The Form 3 reports share options (rights to buy) over ProQR ordinary shares. Each option series has a specified exercise price and expiration date, and all reported positions are held directly by director Bart Filius, according to the ownership details provided.

Why is ProQR director Bart Filius filing this Form 3?

Form 3 is an initial statement of beneficial ownership required for insiders. This filing records director Bart Filius’s existing stock option holdings in ProQR, giving investors transparency into his equity-based compensation and potential future right to acquire ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Filius Bart

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	05/20/2029	Ordinary Shares	12,755	$11.69	D
Share Option (Right to Buy)	(1)	12/31/2029	Ordinary Shares	24,615	$9.91	D
Share Option (Right to Buy)	(1)	12/31/2030	Ordinary Shares	23,239	$4.2	D
Share Option (Right to Buy)	(1)	02/29/2032	Ordinary Shares	23,931	$8.01	D
Share Option (Right to Buy)	(2)	12/31/2032	Ordinary Shares	22,608	$3.41	D
Share Option (Right to Buy)	(3)	12/31/2033	Ordinary Shares	23,489	$1.98	D
Share Option (Right to Buy)	(4)	12/31/2034	Ordinary Shares	22,128	$2.65	D
Share Option (Right to Buy)	(5)	12/31/2035	Ordinary Shares	25,192	$2.02	D

Explanation of Responses:

1. Fully vested.

2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)